CytRx Corp. (CYTR) Ready To Join Broader Rally, Says Wall Street Cheat Sheet Writer

Dec. 05, 2013 6:18 PM ETCYTR
MissionIR profile picture
MissionIR's Blog
133 Followers
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Small cap

Contributor Since 2010

We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to building shareholder value. View our website at www.MissionIR.com MissionIR provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.missionir.com.

CytRx was recently featured in an article by author Tom Meyer, who suggests the biopharm company is on the verge jumping in on a broader rally among companies focused on developing treatment for glioblastoma multiforme, the most common and most aggressive of malignant brain tumors.

To read the full article visit wallstcheatsheet.com/stocks/cytrx-corpor....

Meyers attributes his projection to the recent announcement by CytRx that it has initiated a phase 2 trial of aldoxorubicin, the company's improved formulation of widely used chemotherapeutic agent doxorubicin.

Meyers recaps the progress of peer companies developing similar treatments before jumping into a detailed look at CytRx' phase 2 trial.

"This phase 2 trial follows encouraging preclinical results that were reported earlier this year. Those results indicated that aldoxorubicin demonstrated statistically significant efficacy in the treatment of mice implanted with human GBM tumors. In that study, animals treated with aldoxorubicin had a median survival of 63+ days, compared to just 25 days for animals treated with doxorubicin. Although early, these results certainly indicate that CytRx may have a very bright future," he writes.

In conclusion, the Wall Street Cheat Sheet writer concludes that, "Although investing in a small-cap biotechnology certainly has its risks, CytRx appears to be making all the right moves. Most biotech analysts consider CytRx, Celldex, ImmunoCellular, and Northwest Biotherapeutics to be the leaders for developing an effective treatment for GBM. Given that the latter 3 companies have already seen their rally, it appears to be only a matter of time before CytRx also has its day in the sun."

For more information, visit cytrx.com

MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.